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independent from glomerular filtration rates is of consider-
able interest, as elevated resistin levels in various other
disorders have been associated with both inflammation as
well as malnutrition.3–5
Taking into account that inflammation has been closely
related to malnutrition and in particular to protein–energy
malnutrition,6 one may assume that there is a relationship
between inflammation, plasma resistin levels, and protein
malnutrition in hemodialysis patients and in patients with
chronic kidney disease that is yet to be clarified.
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We thank Fagerberg et al. for their contribution to the
growing body of evidence refuting a causative relationship
between the protein resistin and insulin resistance in
man.1 Indeed, resistin was first described as found in
inflammatory zone (FIZZ)-1, indicating its structural
similarity to several other proinflammatory cytokines.2
Indeed, resistin is expressed mainly in immunocompetent
cells such as leukocytes, and not in adipocytes as had
previously been thought.3,4
Given the fact that even a mild renal function
impairment is associated with a chronic low-grade
inflammation5 and a markedly increased risk of cardio-
vascular death, it is not surprising that the patients in the
study of Fagerberg et al. displayed increased resistin levels
that were also correlated with serum creatinine, C-reactive
protein, and leukocyte counts.
Taken together, we believe that this study further
underscores the relationship between decreasing renal
function and increased risks of inflammation and cardio-
vascular disease. Resistin is one part of this complex, where
we are still looking for a unifying mechanism and an
effective therapy.
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To the Editor: Tissue lanthanum concentrations in the paper
by Slatopolsky et al.1 are similar to our own and others’
findings,2 but have been interpreted very differently.
Comparisons with ‘untreated’ controls are used to highlight
‘marked’ and ‘striking’ increases in deposition in nephrecto-
mized rats, including a 98-fold increase in liver concentra-
tion. When the appropriate comparator is used (lanthanum-
treated rats with normal renal function), there is no statistical
increase in bone and kidney concentrations in the uremic
animals, and only two- to three-fold higher liver concentra-
tions after 15 weeks of treatment. This is entirely consistent
with the absence of any effect of renal failure on systemic
lanthanum exposure3 and a small (two- to three-fold)
increase in first-pass liver exposure, as reported recently for
this uremic model.2 Although tissue concentrations increased
over time (termed ‘progressive accumulation’), their study
was too short to fully reflect the tissue kinetics of lanthanum,
and longer-term studies suggest achievement of steady-state
conditions (Figure 1). Although a maximal dose of
lanthanum (3% (w/w) of diet, 15–22 times the human dose
of 3 g/day)1 was administered for as long as practicable in a
nephrectomized model (limited by death owing to renal
failure), lanthanum concentrations were still only at trace
levels (o3 p.p.m.). As the natural liver concentrations of
other lysosomally transported metals such as iron and copper
are up to 2007 and 55 p.p.m., respectively,4 there would
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appear to be little likelihood that the small quantities of
lanthanum absorbed with therapeutic doses of lanthanum
carbonate will lead to lysosomal overload and toxicity.
Extensive preclinical and clinical safety testing supports this
conclusion.
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In a letter to the editor, Damment1 from Shire Pharma-
ceuticals has questioned the interpretation of the results
from our recently published study in this journal.2 We
looked at the tissue accumulation of lanthanum in kidney,
bone, and liver from normal and uremic lanthanum-
treated rats. In Damment’s letter, he suggests that the only
appropriate comparison is the one between the lantha-
num-treated normal and lanthanum-treated uremic rats.
When looking at tissue accumulation, the appropriate
control for lanthanum-treated uremic rats is untreated
uremic rats. When we made this comparison, we demon-
strated a progressive accumulation of lanthanum in liver
over the entire course of the study. We also observed that
uremia enhances the accumulation of lanthanum as has
been shown by other investigators.3,4 In his letter,
Damment includes a graph showing that lanthanum
accumulation reaches steady-state conditions in longer
term studies. This study, however, was not performed in
uremic rats, but in normal animals. As with Damment’s
study, we also saw that lanthanum accumulation in liver
begin to plateau in lanthanum-treated normal rats.2
Lanthanum, however, will not be prescribed to normal
individuals; thus, these results have no relevance for
hemodialysis patients. On the other hand, Bervoets et al.3
showed significantly greater gastrointestinal absorption of
lanthanum in renal failure. This explains why we see a
greater and progressive accumulation of lanthanum in the
uremic state. Initial concern for lanthanum use had
centered around its potential effects on bone and brain,
as these were the tissues adversely affected by aluminum-
containing phosphate binders.5 We state in our paper that
lanthanum likely has no effect on either of these tissues or
for that matter, kidney. Given the experience with
aluminum-containing phosphate binders, we must be
certain that treatments designed to benefit our patients
will not, in fact, harm them. The jury is still out.
1. Damment SJP. Enlightenment on liver lanthanum exposure. Kidney Int
2006 (in press).
2. Slatopolsky E, Liapis H, Finch JL. Progressive accumulation of lanthanum
in the liver of normal and uremic rats. Kidney Int 2005; 68: 2809–2813.
3. Lacour B, Lucas A, Auchere d et al. Chronic renal failure is associated with
increased tissue deposition of lanthanum after 28-day oral administra-
tion. Kidney Int 2005; 67: 1062–1069. Erratum in: Kidney Int 2005; 68: 427.
4. Bervoets AR, Dams G, Marynissen R et al. Effect of uremia on the
gastrointestinal absorption of lanthanum (La)-carbonate. J Am Soc
Nephrol 2005; 16: 748A.
5. Behets GJ, Dams G, Vercauteren SR et al. Does the phosphate binder
lanthanum carbonate affect bone in rats with chronic renal failure? J Am
Soc Nephrol 2004; 15: 2219–2228.
EA Slatopolsky1, H Liapis1 and J Finch1
1Department of Internal Medicine/Renal, Washington University School of
Medicine, St. Louis, Missouri, USA
Correspondence: EA Slatopolsky, Department of Internal Medicine/Renal,
Washington University School of Medicine, Box 8126, 660 S Euclid Ave., St
Louis, Missouri 63110, USA. E-mail: eslatopo@im.wustl.edu
Downloadable computer models
for maintenance but not acute
renal replacement therapy
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To the Editor: The hemodialysis clearance calculators
developed by Walther et al.1 are a commendable initiative.
However, we wish to draw attention to their limitations for
modelling acute renal replacement therapy in the intensive
care unit. Like Michael’s equation, Dr Addis’ hemodialyzer
clearance (Kd) calculator assumes a fixed configuration for
blood flow (QB) and dialysate flow (QD) within the
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Figure 1 | Long-term liver lanthanum exposure. Liver lanthanum
concentrations in rats treated for 1 day, or 4, 12, 26, or 78 weeks with
1500–2000 mg/kg lanthanum carbonate, 13–17 times the human
dose of 3 g/day of elemental lanthanum. Values are the median and
25th/75th percentiles, n¼ 4–12 rats per time point. Data on file at
Shire Pharmaceuticals Inc., in preparation for publication.
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